3009133-87-0
Chemical Structure
Envudeucitinibum hydrochloride
Synonym(s): Envudeucitinib hydrochloride; ESK-001 hydrochloride
- CAS No.: 3009133-87-0
- Formula:C22H19D6ClN6O3
- Molecular Weight:462.96
InChIKey: FKRBFEUYUROZNF-TXHXQZCNSA-N
SMILES: COC1=C(C2=NN(C([2H])([2H])[2H])C=N2)C=CC=C1NC3=C(C(CC([2H])([2H])[2H])=O)C=NC(NC(C4CC4)=O)=C3.Cl
Biological Activity: Envudeucitinibum (Envudeucitinib; ESK-001) hydrochloride is an orally active and selective TYK2 allosteric inhibitor with an IC50 range of 104-149 nM. Envudeucitinibum hydrochloride blocks JH1 catalytic activity by specifically binding to the JH2 domain of TYK2, thereby inhibiting downstream signaling pathways. Envudeucitinibum hydrochloride is used for research on plaque psoriasis, systemic lupus erythematosus, and other immune-mediated diseases[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Envudeucitinibum hydrochloride | Envudeucitinibum (Envudeucitinib; ESK-001) hydrochloride is an orally active and selective TYK2 allosteric inhibitor with an IC50 range of 104-149 nM. Envudeucitinibum hydrochloride blocks JH1 catalytic activity by specifically binding to the JH2 domain of TYK2, thereby inhibiting downstream signaling pathways. Envudeucitinibum hydrochloride is used for research on plaque psoriasis, systemic lupus erythematosus, and other immune-mediated diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ucpinar S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design. Clinical and translational science. 2024 Dec;17(12):e70094. [Content Brief]
- [2]. Papp KA, et al. Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study. Journal of the American Academy of Dermatology. 2026 Jan;94(1):187-195. [Content Brief]
- [3]. Alumis, Inc., et al. Process of making a TYK2 inhibitor and intermediates thereof. WO2026128621A3. WIPO. 2026-07-02.
